120 related articles for article (PubMed ID: 38186307)
21. Ruthenium (II)-derived organometallic compounds induce cytostatic and cytotoxic effects on mammalian cancer cell lines through p53-dependent and p53-independent mechanisms.
Gaiddon C; Jeannequin P; Bischoff P; Pfeffer M; Sirlin C; Loeffler JP
J Pharmacol Exp Ther; 2005 Dec; 315(3):1403-11. PubMed ID: 16169939
[TBL] [Abstract][Full Text] [Related]
22. Long term effect of curcumin in restoration of tumour suppressor p53 and phase-II antioxidant enzymes via activation of Nrf2 signalling and modulation of inflammation in prevention of cancer.
Das L; Vinayak M
PLoS One; 2015; 10(4):e0124000. PubMed ID: 25860911
[TBL] [Abstract][Full Text] [Related]
23. Neutron activation increases activity of ruthenium-based complexes and induces cell death in glioma cells independent of p53 tumor suppressor gene.
Montel AM; Dos Santos RG; da Costa PR; Silveira-Lacerda EP; Batista AA; Dos Santos WG
Biometals; 2017 Apr; 30(2):295-305. PubMed ID: 28258507
[TBL] [Abstract][Full Text] [Related]
24. Investigation of the role of Bax, p21/Waf1 and p53 as determinants of cellular responses in HCT116 colorectal cancer cells exposed to the novel cytotoxic ruthenium(II) organometallic agent, RM175.
Hayward RL; Schornagel QC; Tente R; Macpherson JS; Aird RE; Guichard S; Habtemariam A; Sadler P; Jodrell DI
Cancer Chemother Pharmacol; 2005 Jun; 55(6):577-83. PubMed ID: 15726367
[TBL] [Abstract][Full Text] [Related]
25. Mechanisms of Targeting the MDM2-p53-FOXM1 Axis in Well-Differentiated Intestinal Neuroendocrine Tumors.
Briest F; Grass I; Sedding D; Möbs M; Christen F; Benecke J; Fuchs K; Mende S; Kaemmerer D; Sänger J; Kunze A; Geisler C; Freitag H; Lewens F; Worpenberg L; Iwaszkiewicz S; Siegmund B; Walther W; Hummel M; Grabowski P
Neuroendocrinology; 2018; 107(1):1-23. PubMed ID: 28910819
[TBL] [Abstract][Full Text] [Related]
26. MEG3 Suppresses Human Pancreatic Neuroendocrine Tumor Cells Growth and Metastasis by Down-Regulation of Mir-183.
Zhang YY; Feng HM
Cell Physiol Biochem; 2017; 44(1):345-356. PubMed ID: 29132136
[TBL] [Abstract][Full Text] [Related]
27. Establishment and characterization of the third non-functional human pancreatic neuroendocrine tumor cell line.
Lou X; Ye Z; Xu X; Jiang M; Lu R; Jing D; Zhang W; Gao H; Wang F; Zhang Y; Chen X; Qin Y; Zhuo Q; Yu X; Ji S
Hum Cell; 2022 Jul; 35(4):1248-1261. PubMed ID: 35394261
[TBL] [Abstract][Full Text] [Related]
28. Loss of nuclear p27 expression and its prognostic role in relation to cyclin E and p53 mutation in gastroenteropancreatic neuroendocrine tumors.
Grabowski P; Schrader J; Wagner J; Hörsch D; Arnold R; Arnold CN; Georgieva I; Stein H; Zeitz M; Daniel PT; Sturm I
Clin Cancer Res; 2008 Nov; 14(22):7378-84. PubMed ID: 19010853
[TBL] [Abstract][Full Text] [Related]
29. Nrf2: a potential therapeutic target for naturally occurring anticancer drugs?
Catanzaro E; Calcabrini C; Turrini E; Sestili P; Fimognari C
Expert Opin Ther Targets; 2017 Aug; 21(8):781-793. PubMed ID: 28675319
[TBL] [Abstract][Full Text] [Related]
30. Dimetallic Ru(II) arene complexes appended on bis-salicylaldimine induce cancer cell death and suppress invasion via p53-dependent signaling.
Rahman FU; Bhatti MZ; Ali A; Duong HQ; Zhang Y; Ji X; Lin Y; Wang H; Li ZT; Zhang DW
Eur J Med Chem; 2018 Sep; 157():1480-1490. PubMed ID: 30282320
[TBL] [Abstract][Full Text] [Related]
31. RITA plus 3-MA overcomes chemoresistance of head and neck cancer cells via dual inhibition of autophagy and antioxidant systems.
Shin D; Kim EH; Lee J; Roh JL
Redox Biol; 2017 Oct; 13():219-227. PubMed ID: 28582730
[TBL] [Abstract][Full Text] [Related]
32. Involvement of Nrf2, p38, B-Raf, and nuclear factor-kappaB, but not phosphatidylinositol 3-kinase, in induction of hemeoxygenase-1 by dietary polyphenols.
Andreadi CK; Howells LM; Atherfold PA; Manson MM
Mol Pharmacol; 2006 Mar; 69(3):1033-40. PubMed ID: 16354769
[TBL] [Abstract][Full Text] [Related]
33. Propofol induces proliferation partially via downregulation of p53 protein and promotes migration via activation of the Nrf2 pathway in human breast cancer cell line MDA-MB-231.
Meng C; Song L; Wang J; Li D; Liu Y; Cui X
Oncol Rep; 2017 Feb; 37(2):841-848. PubMed ID: 28035403
[TBL] [Abstract][Full Text] [Related]
34. Aspirin inhibits cell viability and mTOR downstream signaling in gastroenteropancreatic and bronchopulmonary neuroendocrine tumor cells.
Spampatti M; Vlotides G; Spöttl G; Maurer J; Göke B; Auernhammer CJ
World J Gastroenterol; 2014 Aug; 20(29):10038-49. PubMed ID: 25110431
[TBL] [Abstract][Full Text] [Related]
35. Ginsenoside Rd reverses cisplatin resistance in non-small-cell lung cancer A549 cells by downregulating the nuclear factor erythroid 2-related factor 2 pathway.
Chian S; Zhao Y; Xu M; Yu X; Ke X; Gao R; Yin L
Anticancer Drugs; 2019 Sep; 30(8):838-845. PubMed ID: 31415285
[TBL] [Abstract][Full Text] [Related]
36. Curcumin induces apoptosis in human melanoma cells through a Fas receptor/caspase-8 pathway independent of p53.
Bush JA; Cheung KJ; Li G
Exp Cell Res; 2001 Dec; 271(2):305-14. PubMed ID: 11716543
[TBL] [Abstract][Full Text] [Related]
37. Anti-proliferative and apoptotic effect of gemini curcumin in p53-wild type and p53-mutant colorectal cancer cell lines.
Ebrahimi M; Babaei E; Neri F; Feizi MAH
Int J Pharm; 2021 May; 601():120592. PubMed ID: 33857585
[TBL] [Abstract][Full Text] [Related]
38. Type 2 Diabetes in Neuroendocrine Tumors: Are Biguanides and Statins Part of the Solution?
Herrera-Martínez AD; Pedraza-Arevalo S; L-López F; Gahete MD; Gálvez-Moreno MA; Castaño JP; Luque RM
J Clin Endocrinol Metab; 2019 Jan; 104(1):57-73. PubMed ID: 30265346
[TBL] [Abstract][Full Text] [Related]
39. Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism.
Ren D; Villeneuve NF; Jiang T; Wu T; Lau A; Toppin HA; Zhang DD
Proc Natl Acad Sci U S A; 2011 Jan; 108(4):1433-8. PubMed ID: 21205897
[TBL] [Abstract][Full Text] [Related]
40. Nrf2 signaling pathway in cisplatin chemotherapy: Potential involvement in organ protection and chemoresistance.
Mirzaei S; Mohammadi AT; Gholami MH; Hashemi F; Zarrabi A; Zabolian A; Hushmandi K; Makvandi P; Samec M; Liskova A; Kubatka P; Nabavi N; Aref AR; Ashrafizadeh M; Khan H; Najafi M
Pharmacol Res; 2021 May; 167():105575. PubMed ID: 33771701
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
